News: 2022
MIMETAS Elected Most Innovative Company of the Netherlands
November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award
September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
July 15, 2022
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Read more
FDA Accepts Byondis' BLA for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
July 12, 2022
Byondis acquired the technology for the development of its anti-HER2 ADC drug from Aglaia's portfolio company Syntarga in 2010.
Read more
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed
June 16, 2022
Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular...
Read more
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting
May 27, 2022
ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficac...
Read more
New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging
May 04, 2022
Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other di...
Read more
MIMETAS Expands Adult Stem Cell Organoid License to All Organs
May 03, 2022
MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB...
Read more
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
April 14, 2022
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
Read more
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting
February 17, 2022
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic...
Read more
